Zobrazeno 1 - 10
of 17
pro vyhledávání: '"Hyeyeon Moon"'
Autor:
Hye Ryeon Kim, Minkook Son, Seok Jae Huh, Sang Yi Moon, Hyeyeon Moon, Yeo Wool Kang, Myeongseok Koh, Jong Yoon Lee
Publikováno v:
Frontiers in Oncology, Vol 14 (2024)
BackgroundSeveral previous studies found a positive relationship between metabolic syndrome (MetS) and thyroid cancer (TC) risk. However, there is no research that has studied the relationship between the metabolic score for insulin resistance (METS-
Externí odkaz:
https://doaj.org/article/62f69baef1044ee292ca74a27658282b
Autor:
Hyeyeon Moon, Ju Won Seok, Keunyoung Kim, Hye Young Kim, Mi Kyoung Park, In Joo Kim, Kyoungjune Pak, Sunghwan Suh
Publikováno v:
Kosin Medical Journal, Vol 37, Iss 3, Pp 213-219 (2022)
Background Postsurgical hypocalcemia is the most common and troublesome consequence of thyroidectomy. We investigated the potential role of routine calcium or vitamin D supplementation in preventing postsurgical hypocalcemia. Methods We searched MEDL
Externí odkaz:
https://doaj.org/article/db6d07a81e0649cd9e4db6147bb21384
Autor:
Kyunghee Lim, Hyeyeon Moon, Jong Sung Park, Young-Rak Cho, Kyungil Park, Tae-Ho Park, Moo-Hyun Kim, Young-Dae Kim
Publikováno v:
Journal of Preventive Medicine and Public Health, Vol 55, Iss 4, Pp 351-359 (2022)
Objectives The Regional CardioCerebroVascular Center (RCCVC) project was initiated to improve clinical outcomes for patients with acute myocardial infarction or stroke in non-capital areas of Korea. The purpose of this study was to evaluate the outco
Externí odkaz:
https://doaj.org/article/33f469d06e3e4a4984feb59499218e72
Autor:
Sua Jo, Hyeyeon Moon, Kyungil Park, Chang-Bae Sohn, Jeonghwan Kim, Yong-Seop Kwon, Su Hong Kim
Publikováno v:
Trials, Vol 23, Iss 1, Pp 1-9 (2022)
Abstract Background Dilated cardiomyopathy (DCMP) is characterized by ventricular chamber enlargement and systolic dysfunction which may cause heart failure. Patients with DCMP have overactivation of the renin-angiotensin-aldosterone systems, which c
Externí odkaz:
https://doaj.org/article/949dfaa3b2d34fce964cfd3c14e05920
Publikováno v:
Health and Quality of Life Outcomes, Vol 19, Iss 1, Pp 1-9 (2021)
Abstract Background Ticagrelor has a Class I recommendation for use following percutaneous coronary intervention (PCI) in acute coronary syndrome (ACS). However, ticagrelor needs to be taken twice a day, as compared to clopidogrel. Its adverse effect
Externí odkaz:
https://doaj.org/article/d7fe68558b70442c85b57c1f239465d7
Publikováno v:
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, Vol 9, Iss 10 (2020)
Background This study investigated whether the microvascular dysfunction differed between culprit and non‐culprit vessels in patients with acute coronary syndrome who underwent percutaneous coronary intervention. Methods and Results In 115 prospect
Externí odkaz:
https://doaj.org/article/411e8e62557b46dcb0d4a9293c1e340a
Publikováno v:
Korean Journal of Chemical Engineering. 40:344-351
Publikováno v:
Journal of Korean Medical Science. 38
Publikováno v:
Health and Quality of Life Outcomes, Vol 19, Iss 1, Pp 1-9 (2021)
Health and Quality of Life Outcomes
Health and Quality of Life Outcomes
Background Ticagrelor has a Class I recommendation for use following percutaneous coronary intervention (PCI) in acute coronary syndrome (ACS). However, ticagrelor needs to be taken twice a day, as compared to clopidogrel. Its adverse effects, such a
Publikováno v:
Endocrine Abstracts.